MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

A

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

Novartis AG

Отворен

132.66 1.4

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

130.96

Максимум

133.34

Ключови измерители

By Trading Economics

Приходи

418M

4B

Продажби

660M

14B

P/E

Средно за сектора

18.012

35.739

EPS

2.42

Дивидентна доходност

3.23

Марж на печалбата

28.18

Служители

75,883

EBITDA

-5.8B

4.9M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

-13.64% downside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.23%

3.08%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.2B

240B

Предишно отваряне

131.26

Предишно затваряне

132.66

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Novartis AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.10.2025 г., 08:54 ч. UTC

Значими двигатели на пазара

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

15.09.2025 г., 12:07 ч. UTC

Значими двигатели на пазара

Monte Rosa Therapeutics Shares Soar on Drug Partnership with Novartis

9.09.2025 г., 10:11 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Tourmaline Bio Shares Surge Premarket on Takeover by Novartis

9.09.2025 г., 05:52 ч. UTC

Придобивния, сливания и поглъщания

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

7.08.2025 г., 05:47 ч. UTC

Придобивния, сливания и поглъщания

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

17.07.2025 г., 14:26 ч. UTC

Печалби

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

17.07.2025 г., 06:49 ч. UTC

Печалби

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

17.07.2025 г., 05:41 ч. UTC

Печалби

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

1.10.2025 г., 06:47 ч. UTC

Пазарно говорене

Novartis Bags First FDA Approval for Rhapsido, More Could Follow -- Market Talk

29.09.2025 г., 11:46 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Offer to Expire Oct. 27

29.09.2025 г., 11:45 ч. UTC

Придобивния, сливания и поглъщания

Novartis Has Started Tender Offer to Buy Tourmaline Bio

12.09.2025 г., 16:11 ч. UTC

Печалби

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

9.09.2025 г., 08:09 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Novartis Makes Strategically Meaningful Move With Tourmaline Deal -- Market Talk

9.09.2025 г., 05:04 ч. UTC

Придобивния, сливания и поглъщания

Novartis Offering $48 a Share for Tourmaline

9.09.2025 г., 05:04 ч. UTC

Придобивния, сливания и поглъщания

Novartis: Offer Price Values Tourmaline at $1.4B on Fully Diluted Basis

9.09.2025 г., 05:03 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Tourmaline Bio in Bid to Complement Cardiovascular Pipeline

9.09.2025 г., 05:00 ч. UTC

Придобивния, сливания и поглъщания

Novartis to Buy Tourmaline Bio

11.08.2025 г., 11:16 ч. UTC

Печалби

Rheinmetall, Ørsted, Novartis: Global Stocks in Focus -- WSJ

8.08.2025 г., 11:26 ч. UTC

Пазарно говорене

Novartis Is Getting Closer to Midterm Targets -- Market Talk

8.08.2025 г., 11:07 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Novartis Has Room to Accelerate Dealmaking -- Market Talk

8.08.2025 г., 10:51 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

5.08.2025 г., 10:40 ч. UTC

Пазарно говорене

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

17.07.2025 г., 11:36 ч. UTC

Пазарно говорене

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

17.07.2025 г., 11:26 ч. UTC

Пазарно говорене

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

17.07.2025 г., 07:14 ч. UTC

Пазарно говорене

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

17.07.2025 г., 07:02 ч. UTC

Пазарно говорене
Печалби

Novartis's Results Look Impressive -- Market Talk

17.07.2025 г., 05:09 ч. UTC

Печалби

Novartis 2Q Sales Grew 11% at Constant Currency

17.07.2025 г., 05:08 ч. UTC

Печалби

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

17.07.2025 г., 05:06 ч. UTC

Печалби

Novartis: Mehta's Appointment Is Effective March 2026

17.07.2025 г., 05:05 ч. UTC

Печалби

Novartis: Harry Kirsch Retires After 22 Years With Company

Сравнение с други в отрасъла

Ценова промяна

Novartis AG Прогноза

Ценова цел

By TipRanks

-13.64% надолу

12-месечна прогноза

Среден 113.75 USD  -13.64%

Висок 129 USD

Нисък 100 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Novartis AG през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

1

Купи

3

Задържане

1

Продай

Техническа оценка

By Trading Central

N/A / 112.63Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Strong Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
help-icon Live chat